199 related articles for article (PubMed ID: 18227188)
1. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
Desbois D; Roquebert B; Peytavin G; Damond F; Collin G; Bénard A; Campa P; Matheron S; Chêne G; Brun-Vézinet F; Descamps D;
Antimicrob Agents Chemother; 2008 Apr; 52(4):1545-8. PubMed ID: 18227188
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use.
Brower ET; Bacha UM; Kawasaki Y; Freire E
Chem Biol Drug Des; 2008 Apr; 71(4):298-305. PubMed ID: 18312292
[TBL] [Abstract][Full Text] [Related]
3. In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
Dierynck I; De Meyer S; Lathouwers E; Vanden Abeele C; Van De Casteele T; Spinosa-Guzman S; de Béthune MP; Picchio G
Antivir Ther; 2010; 15(8):1161-9. PubMed ID: 21149923
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 protease mutations and protease inhibitor cross-resistance.
Rhee SY; Taylor J; Fessel WJ; Kaufman D; Towner W; Troia P; Ruane P; Hellinger J; Shirvani V; Zolopa A; Shafer RW
Antimicrob Agents Chemother; 2010 Oct; 54(10):4253-61. PubMed ID: 20660676
[TBL] [Abstract][Full Text] [Related]
5. Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.
Young TP; Parkin NT; Stawiski E; Pilot-Matias T; Trinh R; Kempf DJ; Norton M
Antimicrob Agents Chemother; 2010 Nov; 54(11):4903-6. PubMed ID: 20805393
[TBL] [Abstract][Full Text] [Related]
6. Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir.
Dam E; Lebel-Binay S; Rochas S; Thibaut L; Faudon JL; Thomas CM; Essioux L; Hill A; Schutz M; Clavel F
Antivir Ther; 2007; 12(3):371-80. PubMed ID: 17591027
[TBL] [Abstract][Full Text] [Related]
7. Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
Paulsen D; Liao Q; Fusco G; St Clair M; Shaefer M; Ross L
AIDS Res Hum Retroviruses; 2002 Sep; 18(14):1011-9. PubMed ID: 12396453
[TBL] [Abstract][Full Text] [Related]
8. In vitro antiviral interaction of lopinavir with other protease inhibitors.
Molla A; Mo H; Vasavanonda S; Han L; Lin CT; Hsu A; Kempf DJ
Antimicrob Agents Chemother; 2002 Jul; 46(7):2249-53. PubMed ID: 12069982
[TBL] [Abstract][Full Text] [Related]
9. Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy.
Raugi DN; Smith RA; Ba S; Toure M; Traore F; Sall F; Pan C; Blankenship L; Montano A; Olson J; Dia Badiane NM; Mullins JI; Kiviat NB; Hawes SE; Sow PS; Gottlieb GS;
Antimicrob Agents Chemother; 2013 Jun; 57(6):2751-60. PubMed ID: 23571535
[TBL] [Abstract][Full Text] [Related]
10. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier.
Dierynck I; De Wit M; Gustin E; Keuleers I; Vandersmissen J; Hallenberger S; Hertogs K
J Virol; 2007 Dec; 81(24):13845-51. PubMed ID: 17928344
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy.
Rodés B; Sheldon J; Toro C; Jiménez V; Alvarez MA; Soriano V
J Antimicrob Chemother; 2006 Apr; 57(4):709-13. PubMed ID: 16464891
[TBL] [Abstract][Full Text] [Related]
12. In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir.
Gonzalez LM; Brindeiro RM; Tarin M; Calazans A; Soares MA; Cassol S; Tanuri A
Antimicrob Agents Chemother; 2003 Sep; 47(9):2817-22. PubMed ID: 12936979
[TBL] [Abstract][Full Text] [Related]
13. Inhibition Profiling of Retroviral Protease Inhibitors Using an HIV-2 Modular System.
Mahdi M; Szojka Z; Mótyán JA; Tőzsér J
Viruses; 2015 Nov; 7(12):6152-62. PubMed ID: 26633459
[TBL] [Abstract][Full Text] [Related]
14. Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations.
Gonzalez LMF; Aguiar RS; Afonso A; Brindeiro PA; Arruda MB; Soares MA; Brindeiro RM; Tanuri A
J Gen Virol; 2006 May; 87(Pt 5):1303-1309. PubMed ID: 16603533
[TBL] [Abstract][Full Text] [Related]
15. In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
Masse S; Lu X; Dekhtyar T; Lu L; Koev G; Gao F; Mo H; Kempf D; Bernstein B; Hanna GJ; Molla A
Antimicrob Agents Chemother; 2007 Sep; 51(9):3075-80. PubMed ID: 17576848
[TBL] [Abstract][Full Text] [Related]
16. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.
De Meyer S; Azijn H; Surleraux D; Jochmans D; Tahri A; Pauwels R; Wigerinck P; de Béthune MP
Antimicrob Agents Chemother; 2005 Jun; 49(6):2314-21. PubMed ID: 15917527
[TBL] [Abstract][Full Text] [Related]
17. Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processing.
Davis DA; Soule EE; Davidoff KS; Daniels SI; Naiman NE; Yarchoan R
Antimicrob Agents Chemother; 2012 Jul; 56(7):3620-8. PubMed ID: 22508308
[TBL] [Abstract][Full Text] [Related]
18. Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates.
Bulgheroni E; Citterio P; Croce F; Lo Cicero M; Viganò O; Soster F; Chou TC; Galli M; Rusconi S
J Antimicrob Chemother; 2004 Mar; 53(3):464-8. PubMed ID: 14963061
[TBL] [Abstract][Full Text] [Related]
19. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.
Prado JG; Wrin T; Beauchaine J; Ruiz L; Petropoulos CJ; Frost SD; Clotet B; D'Aquila RT; Martinez-Picado J
AIDS; 2002 May; 16(7):1009-17. PubMed ID: 11953467
[TBL] [Abstract][Full Text] [Related]
20. A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
Amano M; Koh Y; Das D; Li J; Leschenko S; Wang YF; Boross PI; Weber IT; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2007 Jun; 51(6):2143-55. PubMed ID: 17371811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
